stockrow
Sunday 8 November 2026
Export AMRN’s income statement to Excel — free account
Amarin Corporation PLC
AMRNHealthcare Drug Manufacturers General
Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024.
- Revenue
- −20.4%
- EPS
- +103.1%
- Free cash flow
- +172.6%
Quarter to September 2026, against a year earlier
11.61
0.03
+0.26%
Follow AMRN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.36 | 1.40 | 1.78 | 1.54 | |
P/FCF ratio |
43.21 | 11.86 | 21.35 | 7.25 | |
P/Operating CF |
18.96 | 47.43 | 50.26 | 29.44 | |
P/B ratio |
0.63 | 0.67 | 0.75 | 0.61 | |
Price to Tangible BV |
0.65 | 0.69 | 0.77 | 0.63 | |
EV/Sales |
0.02 | 0.06 | 0.19 | (0.19) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 1.15 | |
EV/Operating CF |
0.77 | 0.52 | 2.27 | (0.90) | |
EV/FCF |
0.78 | 0.52 | 2.28 | (0.90) | |
Quick Ratio |
2.21 | 2.32 | 2.48 | 2.48 | |
Current Ratio |
3.34 | 3.48 | 3.67 | 3.50 | |
Net Debt/EBITDA |
53.83 | 28.80 | 27.68 | 188.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.32 | 0.33 | 0.29 | 0.27 | |
Operating CF/Net income |
(12.48) | (0.61) | (0.86) | 37.64 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.91% | 10.34% | 11.31% | 10.63% | |
Selling, General and Administrative Expense of Revenue |
40.76% | 46.78% | 52.56% | 36.25% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
3.28% | 5.16% | 4.98% | 3.48% | |
Graham Net Nets |
1.51 | 1.42 | 1.27 | 1.56 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.39%) | (11.15%) | (8.15%) | (7.04%) | |
Free Cash Flow Yield |
2.31% | 8.43% | 4.68% | 13.80% | |
Revenue per Share |
2.37 | 2.15 | 2.03 | 1.89 | |
Operating CF per Share |
0.74 | 0.30 | 0.32 | 0.44 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.74 | 0.30 | 0.32 | 0.44 | |
Cash per Share |
14.59 | 14.70 | 15.12 | 15.49 | |
Shareholders Equity per Share |
22.13 | 21.45 | 21.31 | 21.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.13 | 21.45 | 21.31 | 21.28 | |
Free Cash Flow |
15.28 | 6.39 | 6.60 | 9.22 | |
Working Capital |
455.42 | 446.37 | 438.56 | 437.74 | |
Net Current Asset Value |
438.39 | 429.67 | 422.01 | 423.21 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 1.05 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
124.56 | 107.39 | 106.02 | 119.44 | |
Average Payables |
42.86 | 46.91 | 31.75 | 38.57 | |
Average Inventory |
180.98 | 171.54 | 167.66 | 171.78 | |
Average Assets |
678.06 | 650.72 | 647.24 | 646.95 | |
Average Common Equity |
472.73 | 461.55 | 454.27 | 451.65 |
Columns are period end dates · fundamentals updated 2 Nov 2026